Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jan;25(1):40-9.
doi: 10.1053/j.jrn.2014.07.006. Epub 2014 Sep 11.

A pilot randomized crossover trial assessing the safety and short-term effects of pomegranate supplementation in hemodialysis patients

Matthew B Rivara  1 , Rajnish Mehrotra  2 , Lori Linke  3 , John Ruzinski  3 , T Alp Ikizler  4 , Jonathan Himmelfarb  2
Affiliations
Randomized Controlled Trial

A pilot randomized crossover trial assessing the safety and short-term effects of pomegranate supplementation in hemodialysis patients

Matthew B Rivara et al. J Ren Nutr. 2015 Jan.

Abstract

Objective: Oxidative stress and systemic inflammation are highly prevalent in patients undergoing maintenance hemodialysis (MHD) and are linked to excess cardiovascular risk. This study examined whether short-term supplementation with pomegranate juice and extract is safe and well tolerated by MHD patients. The secondary aim was to assess the effect of pomegranate supplementation on oxidative stress, systemic inflammation, monocyte function, and blood pressure.

Design: Prospective, randomized, crossover, pilot clinical trial (NCT01562340).

Setting: The study was conducted from March to October 2012 in outpatient dialysis facilities in the Seattle metropolitan area.

Subjects: Twenty-four patients undergoing MHD (men, 64%; mean age, 61 ± 14 years) were randomly assigned to receive pomegranate juice or extract during a 4-week intervention period. After a washout period, all patients received the alternative treatment during a second 4-week intervention period.

Intervention: Patients assigned to receive pomegranate juice received 100 mL of juice before each dialysis session. Patients assigned to receive pomegranate extract were given 1,050 mg of extract daily.

Main outcome measures: The main outcome measures were safety and tolerability of pomegranate juice and extract. Additional secondary outcomes assessed included serum lipids, laboratory biomarkers of inflammation (C-reactive protein and interleukin 6) and oxidative stress (plasma F2 isoprostanes and isofurans), monocyte cytokine production, and predialysis blood pressure.

Results: Both pomegranate juice and extract were safe and well tolerated by study participants. Over the study period, neither treatment had a significant effect on lipid profiles, plasma C-reactive protein, interleukin 6, F2-isoprostane or isofuran concentrations, predialysis systolic or diastolic blood pressure nor changed the levels of monocyte cytokine production.

Conclusions: Both pomegranate juice and extract are safe and well tolerated by patients undergoing MHD but do not influence markers of inflammation or oxidative stress nor affect predialysis blood pressure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no relevant financial interests.

Figures

Figure 1
Figure 1
Flow chart of study populations, including the number of patients who were screened, gave consent, underwent randomization, completed the study treatment and were analyzed for the primary outcome.
Figure 2
Figure 2
Schematic diagram of study protocol showing sequential phases of the study, crossover, and study visits. HD, hemodialysis.
See this image and copyright information in PMC

References

    1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl 12):S16–S23. - PubMed
    1. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–1538. - PubMed
    1. Bayés B, Pastor MC, Bonal J, et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant. 2003;18:106–112. - PubMed
    1. Wang AY-M, Wang M, Woo J, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:2186–2194. - PubMed
    1. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001;12:2747–2752. - PubMed

Publication types

MeSH terms

Associated data